Financial Performance - The group's revenue increased by 43.0% from RMB 1,624.6 million for the year ended December 31, 2022, to RMB 2,323.4 million for the year ended December 31, 2023[2]. - Gross profit rose by 40.1% from RMB 499.5 million in 2022 to RMB 700.0 million in 2023[2]. - Net profit increased by 39.6% from RMB 181.2 million in 2022 to RMB 252.9 million in 2023[2]. - Adjusted net profit grew from RMB 198.4 million in 2022 to RMB 304.7 million in 2023[2]. - Total comprehensive income for the year was RMB 257.9 million, compared to RMB 172.9 million in the previous year[3]. - The company reported a basic earnings per share of RMB 1.06 for the year, up from RMB 0.79 in 2022[6]. - The net profit for the year 2023 was RMB 9,029 thousand, compared to a loss of RMB 2,398 thousand in 2022, indicating a significant turnaround[19]. - Basic earnings per share for 2023 were RMB 0.04, up from a loss of RMB 0.01 per share in 2022[20]. - The net profit attributable to equity holders of the parent company was RMB 252,202,000, compared to RMB 180,854,000 in 2022[40]. - Total revenue for 2023 was RMB 2,323,351 thousand, an increase from RMB 1,624,561 thousand in 2022, representing a growth of approximately 43%[24]. Assets and Liabilities - The company's cash and cash equivalents amounted to RMB 1,301.3 million as of December 31, 2023, up from RMB 994.3 million in 2022[7]. - Current assets increased to RMB 1,837.6 million in 2023 from RMB 1,359.6 million in 2022[7]. - Total assets less current liabilities reached RMB 2,671.1 million, compared to RMB 2,063.9 million in 2022[8]. - Non-current assets totaled RMB 1,541.7 million as of December 31, 2023, compared to RMB 1,258.6 million in 2022[7]. - The total liabilities decreased to RMB 1,506 thousand in 2023 from RMB 8,757 thousand in 2022, a reduction of approximately 83%[18]. - Deferred tax liabilities were RMB 1,506 thousand in 2023, down from RMB 8,757 thousand in 2022, reflecting a decrease of approximately 83%[18]. - The debt-to-equity ratio as of December 31, 2023, was 0.7%[89]. Revenue Sources - Revenue from medical health solutions and product sales was RMB 2,287,100 thousand and RMB 36,251 thousand respectively in 2023, compared to RMB 1,595,717 thousand and RMB 28,844 thousand in 2022[25]. - Revenue from offline medical institutions surged by 49.2% from RMB 1,364.9 million in 2022 to RMB 2,037.1 million in 2023, driven by business growth from newly acquired and existing institutions[71]. - Revenue from the online medical health platform grew by 10.2% from RMB 259.6 million in 2022 to RMB 286.2 million in 2023, due to an increase in patient visits[71]. - Revenue from the sale of medical health products increased by 25.7% from RMB 28.8 million in 2022 to RMB 36.3 million in 2023, mainly due to sales growth from new customers[69]. Customer Growth and Engagement - The company achieved a total of 803,973 new customers in the year ended December 31, 2023, compared to 551,999 in the previous year, reflecting a significant increase of 45.5%[60]. - Cumulative customers reached 3,536,797 by December 31, 2023, up from 2,732,824 in 2022, representing a growth of 29.4%[60]. - The total number of customer visits increased to 4,297,000 in 2023 from 2,945,000 in 2022, marking a rise of 46%[60]. - The customer retention rate improved to 65.2% in 2023 from 64.0% in 2022, indicating effective customer acquisition and retention strategies[60]. Operational Efficiency and Investments - The company has established a digital store system for offline medical institutions to enhance customer interaction and improve service efficiency[53]. - The integration of traditional Chinese medicine and Western medicine aims to provide comprehensive healthcare solutions, particularly in chronic disease management[52]. - The company has implemented a customer relationship management (CRM) system to enhance operational efficiency of the medical professional team[53]. - The establishment of an enterprise resource planning (ERP) system aims to enhance digital operations and management across supply chain, sales, inventory, and accounting[53]. - The company is increasing its investment in research and development to standardize and productize medical health solutions, with plans for more in-house preparations in the future[66]. Corporate Governance and Compliance - The company is committed to maintaining high levels of corporate governance and has complied with all applicable code provisions, except for the separation of the roles of Chairman and CEO[103]. - The company has established an audit committee to assist the board in reviewing compliance, accounting policies, and financial reporting procedures[110]. - The independent auditor has reviewed the preliminary performance announcement, but this does not constitute a certification under Hong Kong auditing standards[111]. - The company is committed to maintaining compliance with the listing rules as outlined in Appendix C3[117]. Future Plans and Strategies - The company plans to apply newly issued but not yet effective Hong Kong Financial Reporting Standards, which may lead to changes in accounting policies but are not expected to significantly impact operational performance[21]. - The company aims to enhance its R&D capabilities, including in-house formulations, with a budget of HKD 74.8 million, of which HKD 44.3 million has been utilized[98]. - The company plans to allocate 60% of the net proceeds (approximately HKD 323.77 million) to expand offline medical institutions by the end of 2027[101]. - The company aims to strengthen its OMO platform and brand value while addressing healthcare accessibility issues for customers[64]. - The company is actively exploring opportunities for mergers and acquisitions to drive growth[117].
固生堂(02273) - 2023 - 年度业绩